v3.23.1
Commitments and Contingencies - Additional Information (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2023
USD ($)
$ / shares
Jan. 31, 2022
USD ($)
Jan. 31, 2023
USD ($)
$ / shares
Jan. 31, 2022
USD ($)
Apr. 30, 2022
USD ($)
$ / shares
Apr. 30, 2021
USD ($)
$ / shares
Apr. 30, 2013
USD ($)
$ / shares
Jun. 03, 2022
$ / shares
Loss Contingencies [Line Items]                
Lessee, operating lease, option to extend     On September 27, 2022, the Company entered into the First Amendment to Lease (the “Lease Amendment”), which amended the Lease Agreement to document the exercise of its option to extend the term of the lease for an additional 64 months, commencing February 1, 2023, and expiring on May 31, 2028 (the “Extension Term”). Pursuant to the amendment, the Company will pay initial monthly payments of $13,129, beginning February 2023, subject to 3% annual increases. The Company will receive a four-month rent concession at the start of the lease extension period on February 1, 2023. The lease also provides for allowances for tenant improvements which may be credited to rent within the first twelve-months of the Extension Term. As a result of this amendment, the Company recognized an additional right-of-use asset and corresponding lease liability of $549,227. The right-of-use asset and liability recognized equals the present value of the remaining payments due under the amended lease.          
Operating lease percentage of annual increase     3.00%          
Operating lease commencing date     Feb. 01, 2023          
Operating lease expiring date     May 31, 2028          
Operating lease option to extend additional lease term     64 months          
Initial monthly payments     $ 13,129          
Additional operating lease liabilities $ 549,227   549,227          
Rent expense $ 45,099 $ 49,422 $ 130,663 $ 139,151 $ 179,364 $ 173,405    
Operating lease incremental borrowing rate 12.00%   12.00%   12.00%      
Common stock, par value | $ / shares $ 0.001   $ 0.001   $ 0.001 $ 0.001   $ 0.001
Notes payable $ 1,130,000   $ 1,130,000   $ 6,071,807 $ 2,880,200    
Selling, general, and administrative expenses $ 667,235 $ 403,158 $ 2,590,227 $ 1,089,301 1,714,350 874,620    
Royalty Agreements                
Loss Contingencies [Line Items]                
Royalty not paid balance amount             $ 3,500,000  
Royalties total amount             $ 3,500,000  
Common stock, par value | $ / shares             $ 68.75  
Receipt of bona fide offer valuing common stock             $ 68.75  
Aggregate payment of royalties             3,000,000  
Minimum payments         $ 20,000 $ 20,000    
Percentage of annual increase in long term purchase commitment         3.00% 3.00%    
Selling, general, and administrative expenses         $ 500 $ 1,500    
Royalty Agreements | Maximum                
Loss Contingencies [Line Items]                
Sales rate of product         50      
Royalty Agreements | Minimum                
Loss Contingencies [Line Items]                
Sales rate of product         35      
Royalty Agreements | Secured Convertible Promissory Notes                
Loss Contingencies [Line Items]                
Notes payable             1,500,000  
Royalty Agreements | Loan and Security Agreement                
Loss Contingencies [Line Items]                
Notes payable             1,000,000  
Royalty Agreements | MyoVista Devices                
Loss Contingencies [Line Items]                
Royalty payment upon paid for each device amount             200  
Royalty Agreements | 2,400 MyoVista Devices                
Loss Contingencies [Line Items]                
Royalty payment upon paid for each device amount             $ 500